BlackRock's position in MBX Biosciences Common Stock is currently worth $90.9M. That's 0.00% of their equity portfolio (2105th largest holding). The investor owns 8.60% of the outstanding MBX Biosciences Common Stock stock. The stake costed the investor $53.8M, netting the investor a gain of 69% so far.